15 May 2018 in Analytical Chemistry
23 March 2021 in The Analyst
The COVID-19 pandemic has put the spotlight on the urgent need for point-of-care nucleic acid tests (NATs) for infectious diseases.
6 April 2021 in The Analyst
An HIV detection assay featuring a low-cost μPAD for electrophoretic RNA extraction and rapid isothermal nucleic acid amplification.
25 October 2022 in PLOS ONE
Over 71 million people are infected with hepatitis C virus (HCV) worldwide, and approximately 400,000 global deaths result from complications of untreated chronic HCV. Pan-genomic direct-acting antivirals (DAAs) have recently become widely available and feature high cure rates in less than 12 weeks of treatment. The rollout of DAAs is reliant on diagnostic tests for HCV RNA to identify eligible patients with viremic HCV infections. Current PCR-based HCV RNA assays are restricted to well-resourced central laboratories, and there remains a prevailing clinical need for expanded access to decentralized HCV RNA testing to provide rapid chronic HCV diagnosis and linkage to DAAs in outpatient clinics. This paper reports a rapid, highly accurate, and minimally instrumented assay for HCV RNA detection using reverse transcription recombinase polymerase amplification (RT-RPA). The assay detects all HCV genotypes with a limit of detection of 25 copies per reaction for genotype 1, the most prevalent in the United States and worldwide. The clinical sensitivity and specificity of the RT-RPA assay were both 100% when evaluated using 78 diverse clinical serum specimens. The accuracy, short runtime, and low heating demands of RT-RPA may enable implementation in a point-of-care HCV test to expand global access to effective treatment via rapid chronic HCV diagnosis.
14 June 2022 in Lab on a Chip
We report a novel method for the quantification of isothermal amplification reactions on paper membranes using discrete fluorescent amplification nucleation sites.
6 April 2020 in ACS Sensors